Sildenafil Teva
From £3.99
Clinical Evidence Supporting Viagra Treatment Costs
Foundational Clinical Research
Viagra's development involved rigorous clinical trials establishing its efficacy and safety profile. Initial phase III studies demonstrated that sildenafil citrate significantly improved erectile function compared to placebo, with success rates ranging from 60-85% depending on underlying causes of erectile dysfunction. These pivotal trials involved over 3,000 men and established the evidence base justifying Viagra's position as a first-line treatment option.
Comparative Effectiveness Research
Multiple studies have examined the clinical equivalence between branded Viagra and generic sildenafil formulations. Research published in peer-reviewed journals confirms that both contain identical active ingredients in equivalent bioavailable forms. Patients choosing between branded and generic options can be confident in comparable therapeutic outcomes, with cost considerations being the primary differentiating factor rather than clinical effectiveness.
Long-term Safety Evidence
Over 25 years of post-marketing surveillance has generated substantial safety data supporting Viagra's use in appropriate patients. Large-scale epidemiological studies involving tens of thousands of patients demonstrate acceptable safety profiles when prescribed following proper clinical assessment. This extensive real-world evidence supports the cost-effectiveness of treatment by establishing predictable risk-benefit ratios for healthcare decision-making.
Dosage Optimization Studies
Clinical research has established evidence-based dosing protocols maximizing treatment value. Studies demonstrate that starting with 50mg doses and adjusting based on individual response optimizes both clinical outcomes and cost-effectiveness. Research indicates that approximately 70% of patients achieve satisfactory results with standard dosing, while 15-20% benefit from dose adjustments to 25mg or 100mg formulations.
Economic Health Outcomes Research
Health economics studies evaluate the broader cost implications of ED treatment beyond medication pricing. Research demonstrates that effective treatment may reduce healthcare utilization for psychological and relationship-related issues. Quality of life studies using validated instruments show significant improvements in patient-reported outcomes, supporting the therapeutic value proposition of both branded and generic options available through regulated UK pharmacy services.
Patient Selection Research
Clinical evidence guides appropriate patient selection for optimal treatment outcomes and cost-effectiveness. Studies identify factors predicting treatment success, including patient age, underlying medical conditions, and concurrent medications. This research supports the requirement for clinical assessment by qualified prescribers, ensuring treatment appropriateness and maximizing the likelihood of successful therapeutic outcomes regardless of whether patients choose branded or generic formulations.
